Q: What is Relatlimab used for?

Relatlimab is used to treat unresectable or metastatic melanoma (in combination with nivolumab ).

Q: How does Relatlimab work?

Immune Checkpoint Inhibition Relatlimab is a type of monoclonal antibody known as an immune checkpoint inhibitor. The immune system naturally uses checkpoints to keep immune responses under control and prevent the body from attacking its own healthy cells. However, some cancer cells can exploit these checkpoints to hide from the immune system. Targeting LAG-3 Relatlimab specifically targets a protein called lymphocyte-activation gene 3 (LAG-3). This protein is found on the surface of T cells, which are white blood cells responsible for fighting diseases and tumors. When LAG-3 is activated, it acts like a brake, slowing down or stopping the T cells from attacking. By binding to and blocking the LAG-3 protein, relatlimab helps to: Release the brakes on the immune system. Reactivate T cells that have become exhausted or inactive. Allow the immune system to better identify and destroy melanoma cells. Combination Therapy Relatlimab is used in combination with nivolumab, another checkpoint inhibitor that targets a different protein called PD-1. Because these two drugs block different pathways that cancer cells use to evade the immune system, using them together may help the immune system fight the cancer more effectively than using one drug alone.

Q: What are the active ingredients in Relatlimab?

The active ingredient in Relatlimab is relatlimab .

Q: What are the side effects of Relatlimab?

Common side effects of Relatlimab may include: Fatigue Rash Pruritus Always consult with a healthcare professional about potential side effects.

Q: What drug class is Relatlimab?

Relatlimab belongs to the immune checkpoint inhibitor drug class.

Q: What is the dosage of Relatlimab and how do I take it?

Administration Relatlimab is given as an injection into a vein through an intravenous (IV) infusion. This procedure is performed by a doctor or nurse in a medical setting, such as a hospital or specialized clinic. The infusion process generally takes about 30 minutes to complete. During and after the infusion, healthcare providers will monitor you for any immediate reactions to the medication. Dosing Schedule This medication is usually administered once every four weeks. Your healthcare provider will determine the exact schedule based on your condition and how you respond to the treatment. Missed Doses It is important to keep all scheduled appointments for your infusions. If you miss an appointment, contact your healthcare provider as soon as possible to reschedule. Maintaining a consistent treatment schedule is necessary for the medication to be effective.

Q: Is Relatlimab safe during pregnancy and breastfeeding?

Pregnancy Relatlimab can cause serious harm to an unborn baby. Healthcare providers typically perform a pregnancy test before starting treatment to ensure a patient is not pregnant. If you are pregnant or planning to become pregnant, discuss the potential risks with your healthcare team. Patients who can become pregnant should use effective birth control during treatment and for at least 5 months after the final dose. If pregnancy occurs during treatment, notify a doctor right away. Breastfeeding It is not known if relatlimab passes into breast milk. Because of the risk of serious side effects in a nursing infant, breastfeeding is not recommended during treatment and for at least 5 months after the last dose.

Q: What is the FDA approval status of Relatlimab?

FDA Approval Status The U.S. Food and Drug Administration (FDA) approved relatlimab in March 2022. It is currently approved only as a fixed-dose combination with nivolumab, administered as an intravenous infusion. Approved Indications This combination treatment is indicated for adult and pediatric patients 12 years of age or older with the following conditions: Unresectable melanoma: Skin cancer that cannot be removed by surgery. Metastatic melanoma: Skin cancer that has spread to other parts of the body. Regulatory Background The approval was based on clinical trial data demonstrating that the combination of relatlimab and nivolumab improved progression-free survival compared to nivolumab alone. Relatlimab is the first LAG-3 blocking antibody to receive FDA approval. While the medication carries risks for serious immune-related adverse reactions, there are currently no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) specifically mandated for this product beyond standard clinical monitoring.

Question 1

What is Relatlimab?

Accepted Answer

Relatlimab is a lymphocyte activation gene-3 (LAG-3) blocking antibody. It works by binding to LAG-3 proteins on immune cells, which helps restore the body's ability to recognize and attack cancer cells.

This medication is a type of immunotherapy that is often used in combination with other treatments to strengthen the immune response against tumors.

Question 2

What is Relatlimab used for?

Accepted Answer

Relatlimab is used to treat unresectable or metastatic melanoma (in combination with nivolumab).

Question 3

How does Relatlimab work?

Accepted Answer

Immune Checkpoint Inhibition

Relatlimab is a type of monoclonal antibody known as an immune checkpoint inhibitor. The immune system naturally uses checkpoints to keep immune responses under control and prevent the body from attacking its own healthy cells. However, some cancer cells can exploit these checkpoints to hide from the immune system.

Targeting LAG-3

Relatlimab specifically targets a protein called lymphocyte-activation gene 3 (LAG-3). This protein is found on the surface of T cells, which are white blood cells responsible for fighting diseases and tumors. When LAG-3 is activated, it acts like a brake, slowing down or stopping the T cells from attacking.

By binding to and blocking the LAG-3 protein, relatlimab helps to:

Release the brakes on the immune system.
Reactivate T cells that have become exhausted or inactive.
Allow the immune system to better identify and destroy melanoma cells.

Combination Therapy

Relatlimab is used in combination with nivolumab, another checkpoint inhibitor that targets a different protein called PD-1. Because these two drugs block different pathways that cancer cells use to evade the immune system, using them together may help the immune system fight the cancer more effectively than using one drug alone.

Question 4

What are the active ingredients in Relatlimab?

Accepted Answer

The active ingredient in Relatlimab is relatlimab.

Question 5

What are the side effects of Relatlimab?

Accepted Answer

Common side effects of Relatlimab may include:

Fatigue
Rash
Pruritus

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Relatlimab?

Accepted Answer

Relatlimab belongs to the immune checkpoint inhibitor drug class.

Question 7

What is the dosage of Relatlimab and how do I take it?

Accepted Answer

Administration

Relatlimab is given as an injection into a vein through an intravenous (IV) infusion. This procedure is performed by a doctor or nurse in a medical setting, such as a hospital or specialized clinic.

The infusion process generally takes about 30 minutes to complete. During and after the infusion, healthcare providers will monitor you for any immediate reactions to the medication.

Dosing Schedule

This medication is usually administered once every four weeks. Your healthcare provider will determine the exact schedule based on your condition and how you respond to the treatment.

Missed Doses

It is important to keep all scheduled appointments for your infusions. If you miss an appointment, contact your healthcare provider as soon as possible to reschedule. Maintaining a consistent treatment schedule is necessary for the medication to be effective.

Question 8

Is Relatlimab safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Relatlimab can cause serious harm to an unborn baby. Healthcare providers typically perform a pregnancy test before starting treatment to ensure a patient is not pregnant. If you are pregnant or planning to become pregnant, discuss the potential risks with your healthcare team.

Patients who can become pregnant should use effective birth control during treatment and for at least 5 months after the final dose. If pregnancy occurs during treatment, notify a doctor right away.

Breastfeeding

It is not known if relatlimab passes into breast milk. Because of the risk of serious side effects in a nursing infant, breastfeeding is not recommended during treatment and for at least 5 months after the last dose.

Question 9

What forms and strengths does Relatlimab come in?

Accepted Answer

Relatlimab is administered as an injection into a vein by a healthcare professional. It is provided as a liquid solution in a vial.

This medication is currently available only as a fixed-dose combination with nivolumab. It is not available as a standalone product.

Intravenous solution

Question 10

What is the FDA approval status of Relatlimab?

Accepted Answer

FDA Approval Status

The U.S. Food and Drug Administration (FDA) approved relatlimab in March 2022. It is currently approved only as a fixed-dose combination with nivolumab, administered as an intravenous infusion.

Approved Indications

This combination treatment is indicated for adult and pediatric patients 12 years of age or older with the following conditions:

Unresectable melanoma: Skin cancer that cannot be removed by surgery.
Metastatic melanoma: Skin cancer that has spread to other parts of the body.

Regulatory Background

The approval was based on clinical trial data demonstrating that the combination of relatlimab and nivolumab improved progression-free survival compared to nivolumab alone. Relatlimab is the first LAG-3 blocking antibody to receive FDA approval. While the medication carries risks for serious immune-related adverse reactions, there are currently no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) specifically mandated for this product beyond standard clinical monitoring.

Question 11

What should I know about Relatlimab and fda approval?

Accepted Answer

FDA Approval Overview

The U.S. Food and Drug Administration (FDA) approved relatlimab in March 2022. It is approved for use only as a fixed-dose combination with another immunotherapy drug, nivolumab. This combination is marketed under the brand name Opdualag.

Approved Indications

The FDA has approved the combination of relatlimab and nivolumab for the treatment of:

Adults with unresectable or metastatic melanoma.
Pediatric patients 12 years of age and older who weigh at least 40 kilograms (about 88 pounds) with unresectable or metastatic melanoma.

Unresectable melanoma is skin cancer that cannot be removed through surgery. Metastatic melanoma is cancer that has spread from the skin to other parts of the body.

Drug Class Significance

Relatlimab is the first drug in a class called LAG-3 blocking antibodies to receive FDA approval. It works by blocking a protein called LAG-3 on immune cells, which helps the immune system more effectively attack melanoma cells.

Relatlimab

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

Found an Error?

Find Discounts for Relatlimab

Hospitals.net Disclosure